Role of Forkhead Box O Proteins in Hepatocellular Carcinoma Biology and Progression (Review)

• Main Authors: Shaojie Yang, Liwei Pang, Wanlin Dai, Shuodong Wu, Tengqi Ren, Yunlong Duan, Yuting Zheng, Shiyuan Bi, Xiaolin Zhang, Jing Kong
• Format: Article
• Language: English
• Published: Frontiers Media S.A. 2021-05-01
• Series: Frontiers in Oncology
• Subjects: forkhead box O 1; forkhead box O 3; forkhead box O 4; forkhead box O 6; hepatocellular carcinoma
• Online Access: https://www.frontiersin.org/articles/10.3389/fonc.2021.667730/full

Hepatocellular carcinoma (HCC), the most common type of malignant tumor of the digestive system, is associated with high morbidity and mortality. The main treatment for HCC is surgical resection. Advanced disease, recurrence, and metastasis are the main factors affecting prognosis. Chemotherapy and radiotherapy are not sufficiently efficacious for the treatment of primary and metastatic HCC; therefore, optimizing targeted therapy is essential for improving outcomes. Forkhead box O (FOXO) proteins are widely expressed in cells and function to integrate a variety of growth factors, oxidative stress signals, and other stimulatory signals, thereby inducing the specific expression of downstream signal factors and regulation of the cell cycle, senescence, apoptosis, oxidative stress, HCC development, and chemotherapy sensitivity. Accordingly, FOXO proteins are considered multifunctional targets of cancer treatment. The current review discusses the roles of FOXO proteins, particularly FOXO1, FOXO3, FOXO4, and FOXO6, in HCC and establishes a theoretical basis for the potential targeted therapy of HCC.